Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets $108mm for Sientra

Executive Summary

Sientra Inc. (medical aesthetic devices) netted $108mm through the public offering of 20mm shares (including the overallotment) at $5.75. The company will use the proceeds to carry out sales and marketing initiatives, expand commercially in the US and globally, and fund R&D. Potentially, some of the funds may also support future acquisitions or investments in complementary businesses, products, or technologies. Sientra offers both a portfolio of breast products (including implants, tissue expanders, and scar management products sold to plastic surgeons) as well as the miraDry system (for reduction of underarm sweat, odor, and hair), with a 2019 sales outlook of $44-46mm and $35-37mm for the segments, respectively.
Deal Industry
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies